The FDA granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics, as an adjunctive treatment for adults with negative symptoms of schizophrenia.

Mental Health & Wellbeing

Depression, anxiety, suicide prevention, youth mental health, therapeutic approaches, neurodiversity, and access to psychiatric care.

4 debates·271 claims·80 news stories

94 claims·5 news stories